- Waldenström Macroglobulinemia
- Melanoma
- Bladder Cancer
- Brain Cancer
- Breast Cancer
- Childhood Cancers
- Gastric Cancer
- Gynecologic Cancer
- Head & Neck Cancer
- Immunotherapy
- Kidney Cancer
- Leukemia
- Liver Cancer
- Lung Cancer
- Lymphoma Cancer
- Mesothelioma
- MPN
- MDS
- Myeloma
- Prostate Cancer
- Rare Cancers
- Sarcoma
- Skin Cancer
- Testicular Cancer
- Thyroid Cancer
New Version of an Old Chemotherapy May Reduce Risk of Cardiotoxicity in AML
Liposomal anthracycline may allow for higher dosing with less cardiotoxicity in childhood AML patients.
Anthracyclines are chemotherapy drugs that are effective in treating acute myeloid leukemia (AML) in children, but the risk to these pediatric patients of developing heart problems later in life increases with the cumulative dose of the drug given. When first treating the disease, doctors try to use the highest possible chemotherapy dose in order to drive the cancer into remission. Yet, a potent regimen is tempered by concern about side effects.
A study that included 521 pediatric participants suggested that a liposomal formulation of the anthracycline daunorubicin may allow for higher dosing with less cardiotoxicity than standard induction therapy. By using a lipid-based form of the drug, doctors could intensify the amount of chemotherapy because of the way it is distributed in the body and the timeframe in which it remains in circulation and is exposed to heart tissue.
Shannen Doherty Gives a Cancer Update, ‘Kool & the Gang’ Member Dies From Cancer and More
December 1st 2023As Shannen Doherty revealed her cancer diagnoses and upcoming podcast and a woman with breast cancer completed her bucket list, here is what’s happening in the oncology space this week.
Read More
Author, Cancer Survivor Channeled Her Grief Into a Series of Books
November 2nd 2023Charlene Wexler, the Chicago-based author of the Laughter and Tears series of novels, is an ovarian cancer survivor who now has skin cancer. She told CURE® about how her son’s death from leukemia led to her re-invention as a writer.
Listen
FDA Biologics License Application Filed for Obe-Cel for Adult R/R B-ALL
November 29th 2023Following promising study results, a Biologics License Application has been filed with the FDA for obe-cel (obecabtagene autoleucel), a CAR-T cell therapy for patients with relapsed/refractory (r/r) adult B-cell acute lymphoblastic leukemia (ALL).
Read More
